



December 10, 2019

Marge Watchorn, Deputy Director, Practitioner Services  
Centers for Medicare and Medicaid Services  
Department of Health and Human Services  
Attention CMS-1693-IFC  
P. O. Box 8010  
Baltimore, MD 21244-8016

**Re: Our Request /Petition for Reevaluation to the  
Recent Misvalue of CPT code 53852**

Dear Mrs. Watchorn:

Happy Holidays! We understand this is a very busy time for you and would like to follow up with you about the letter we sent to you on November 12, 2019. The letter states why we believe the CPT code for our Prolieve (3<sup>rd</sup> Generation) and only **Thermodilatation** therapy device, should be reevaluated and was not justified for the major reduction in reimbursement like other (1<sup>st</sup> and 2<sup>nd</sup> Generation) *Thermotherapy* treatment devices. Without the reevaluation as stated we, and approximately 200 Urologists in the USA who provide the Prolieve treatment in their offices, can no longer economically make this treatment available to the many patients who can benefit by its usage.

We believe our Prolieve treatment provides significant clinical safety and efficacy advantages for the patients as well as dramatically saves the overall cost of healthcare for a large number of men with BPH. Without the time sensitive revaluation, it will reduce the treatment options to what the urologists can offer in their offices and for the benefits of their patients and to the economic well-being of Medifocus Inc. Over 100,000 men in the USA have successfully been treated with Prolieve and it is our desire to have this available to many more.

Regards,

A handwritten signature in black ink, appearing to read 'John Mon', is written over the typed name. The signature is fluid and cursive.

John Mon

JM/fre

cc: AMA RUC/AUA CPT Committee